A phase II randomized trial of lapatinib with either vinorelbine or capecitabine in ErbB2-overexpressing first- and second-line metastatic breast cancer (MBC).

W Janni(University Hospital Ulm), W. Wiest, Molly Lim, Jose Alvarez, Bogusława Karaszewska(State University of Applied Sciences in Konin), C.A. Papadimitriou

Journal of Clinical Oncology

May 20, 2010

10.1200/jco.2010.28.15_suppl.tps135

Cited by 2

Related Papers

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

|The Lancet|2012|3k

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

|New England Journal of Medicine|2014|2.7k

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

|New England Journal of Medicine|2019|1.4k

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet Oncology|2017|347

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

|Journal of Clinical Oncology|2022|334